Comparação da produção de Ácidos Graxos de Cadeia Curta entre pacientes com Doença Inflamatória Intestinal e indivíduos saudáveis
Carregando...
Data
2022-12-22
Autores
Oliveira, Letícia Patrocinio
Título da Revista
ISSN da Revista
Título de Volume
Editor
Universidade Estadual Paulista (Unesp)
Resumo
A Doença Inflamatória Intestinal (DII) compreende duas principais doenças, a doença de Crohn (DC) e a Retocolite Ulcerativa (RCU), essas doenças caracterizadas pela complexa interação entre fatores genéticos, imunológicos, microbianos e ambientais. A microbiota intestinal refere-se a variedade de microrganismos vivos que colonizam o intestino, e devido a inflamação característica da doença observa-se alterações na microbiota intestinal. Uma das principais funções da microbiota intestinal é a produção de ácidos graxos de cadeira curta (AGCCs), e devido as estas alterações acredita-se que por consequência haja alterações no perfil de AGCCs nos indivíduos portadores de DII. O presente estudo teve como objetivo avaliar e comparar o perfil dos AGCCs em pacientes com DII e indivíduos saudáveis, entre DC e RCU e atividade e remissão das doenças. Foram analisados parâmetros sociodemográficos, clínicos e endoscópicos de indivíduos com DII e comparados com indivíduos saudáveis, entre DC e RCU, entre atividade e remissão da doença clínica e endoscópica. As dosagens de ácidos butírico, propriônico, acético e calprotectina foram obtidas através de amostras fecais. Os indivíduos com DII apresentaram valores significativamente maiores de AGCC que os saudáveis. Tais achados podem ser explicados pelas alterações da microbiota destes pacientes, diferença no perfil de produção e absorção dos AGCCs, pelo grau de atividade da doença e influência da dieta. Os achados deste estudo reforçam a diferença entre a microbiota dos pacientes com DII e indivíduos saudáveis, mas ainda se faz necessário o aprofundamento destas análises para elucidar as principais etapas que diferenciam a produção e absorção destes compostos. Estudos sobre alterações nas comunidades bacterianas em pacientes com DII são cada vez mais presentes, entretanto, ainda são poucos os estudos que avaliaram o perfil de produção, absorção e excreção de AGCCs nos portadores de DII, sendo necessário aumentar o conhecimento sobre a relação entre microbiota e a produção dos AGCCs nestes pacientes possibilitando compreender suas diferenças e nortear o desenvolvimento de novos alvos de tratamento no futuro.
Inflammatory Bowel Disease (IBD) comprises two main diseases, Crohn's disease (CD) and Ulcerative Colitis (UC), these diseases are characterized by the complex interaction between genetic, immunological, microbial and environmental factors. The intestinal microbiota refers to the variety of living microorganisms that colonize the intestine, and due to the inflammation characteristic of the disease, changes in the intestinal microbiota are ob intestinal microbiota is the production of shortserved. One of the main functions of the chain fatty acids (SCFAs), and due to these changes, it is believed that consequently there are changes in the profile of AGCCs in individuals with IBD. The present s tudy aimed to evaluate and compare the profile of SCFAs in patients with IBD and healthy individuals, between CD and UC and disease activity and remission. Sociodemographic, clinical and endoscopic parameters of individuals with IBD were analyzed and compa red with healthy individuals, between CD and UC, between clinical and endoscopic disease activity and remission. The dosages of butyric, propionic, acetic and calprotectin acids were obtained through fecal samples. Individuals with IBD had significantly hi gher SCFA values than healthy ones. Such findings can be explained by changes in the microbiota of these patients, difference in the profile of production and absorption of SCFAs, by the degree of disease activity and influence of diet. The findings of t his study reinforce the difference between the microbiota of patients with IBD and healthy individuals, but it is still necessary to deepen these analyzes to elucidate the main steps that differentiate the production and absorption of these compounds. Stu dies on changes in bacterial communities in patients with IBD are increasingly present, however, there are still few studies that have evaluated the profile of production, absorption and excretion of SCFAs in IBD patients, making it necessary to increase k nowledge about the relationship between microbiota and the production of AGCCs in these patients, making it possible to understand their differences and guide the development of new treatment targets in the future.
Inflammatory Bowel Disease (IBD) comprises two main diseases, Crohn's disease (CD) and Ulcerative Colitis (UC), these diseases are characterized by the complex interaction between genetic, immunological, microbial and environmental factors. The intestinal microbiota refers to the variety of living microorganisms that colonize the intestine, and due to the inflammation characteristic of the disease, changes in the intestinal microbiota are ob intestinal microbiota is the production of shortserved. One of the main functions of the chain fatty acids (SCFAs), and due to these changes, it is believed that consequently there are changes in the profile of AGCCs in individuals with IBD. The present s tudy aimed to evaluate and compare the profile of SCFAs in patients with IBD and healthy individuals, between CD and UC and disease activity and remission. Sociodemographic, clinical and endoscopic parameters of individuals with IBD were analyzed and compa red with healthy individuals, between CD and UC, between clinical and endoscopic disease activity and remission. The dosages of butyric, propionic, acetic and calprotectin acids were obtained through fecal samples. Individuals with IBD had significantly hi gher SCFA values than healthy ones. Such findings can be explained by changes in the microbiota of these patients, difference in the profile of production and absorption of SCFAs, by the degree of disease activity and influence of diet. The findings of t his study reinforce the difference between the microbiota of patients with IBD and healthy individuals, but it is still necessary to deepen these analyzes to elucidate the main steps that differentiate the production and absorption of these compounds. Stu dies on changes in bacterial communities in patients with IBD are increasingly present, however, there are still few studies that have evaluated the profile of production, absorption and excretion of SCFAs in IBD patients, making it necessary to increase k nowledge about the relationship between microbiota and the production of AGCCs in these patients, making it possible to understand their differences and guide the development of new treatment targets in the future.
Descrição
Palavras-chave
Disbiose, Ácidos graxos de cadeia curta, Doença inflamatória intestinal, Short chain fatty acids, Inflammatory bowel disease, Dysbiosis